Figure 3

Cumulative probability plots of mean change in modified total Sharp score. Cumulative probability plots displaying the changes in modified total Sharp score (ΔmTSS) from baseline to week 24 were generated for (a) patients with baseline C-reactive protein (CRP) < 1.0 mg/dl and (b) patients with baseline CRP ≥1.0 mg/dl. For each CRP category, the placebo curve is above the adalimumab curve, indicating greater radiographic progression.